6533b86cfe1ef96bd12c82de

RESEARCH PRODUCT

Tocilizumab as first treatment option in optic neuropathy secondary to Graves' orbitopathy.

Isabel Pascual-campsJ. TodolíR. Molina-palleteE. España-gregoriE. España-gregoriM. A. Bort-martí

subject

Malemusculoskeletal diseasesDecompressionmedicine.medical_specialtyDecompressionmedicine.medical_treatmentVisual Acuity030209 endocrinology & metabolismdysthyroid optic neuropathyAntibodies Monoclonal HumanizedOptic neuropathy03 medical and health scienceschemistry.chemical_compoundGraves' orbitopathytocilizumab0302 clinical medicineTocilizumabRefractoryOptic Nerve DiseasesmedicineHumansbusiness.industryTreatment optionsMiddle Agedmedicine.diseaseeye diseasesSurgeryRadiation therapyGraves OphthalmopathyOphthalmologychemistry030221 ophthalmology & optometryPrimary treatmentVisual FieldsIntravenous steroidsbusinessTomography Optical Coherencesteroids

description

Dysthyroid optic neuropathy (DON) is one of the complications that can affect Graves' orbitopathy (GO) patients. Its prevalence is estimated at less than 5%. It is usually treated with intravenous steroids, radiotherapy or orbital decompression. Tocilizumab has been proposed as a treatment option in cases of GO refractory to steroid treatment, with good clinical results. Our aim is to report the case of a patient with optic neuropathy secondary to GO treated with tocilizumab as primary treatment option.

yearjournalcountryeditionlanguage
2018-02-08
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=9632